Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15661581 | 0.79 | HTT (0.44) | HTTKMT2ATP53CYP1A2CYP3A4 | |
| SCHEMBL31569579 | 0.77 | HTT (0.43) | HTTKMT2AEPHB4 | |
| SCHEMBL503108 | 0.77 | HTT (0.43) | HTTKMT2AEPHB4 | |
| SCHEMBL18708648 | 0.77 | HTT (0.43) | HTTKMT2AEPHB4 | |
| SCHEMBL24682761 | 0.74 | HTT (0.40) | HTTKMT2AEPHB4 | |
| SCHEMBL1565247 | 0.74 | HTT (0.40) | HTTKMT2A | |
| SCHEMBL11709628 | 0.74 | HTT (0.40) | HTTKMT2AGAAEPHB4 | |
| SCHEMBL20778042 | 0.74 | HTT (0.40) | HTTKMT2AEPHB4 | |
| SCHEMBL15203400 | 0.74 | NOS3 (0.40) | — | |
| SCHEMBL4053831 | 0.74 | DYRK1A (0.36) | HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112867716-A | Solid forms of FGFR inhibitors and methods for their preparation | 因赛特公司 | 2021-05-28 | — | — | CN | claimed |
| EP-3788047-A2 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | Incyte Corporation (US) | 2021-03-10 | — | — | EP | claimed |
| US-20190337948-A1 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | WILMINGTON PHARMATECH | 2019-11-07 | — | — | US | claimed |
| US-20260108521-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2026-04-23 | — | — | US | disclosed |
| EP-4727647-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | The Broad Institute Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103465-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-12552792-B2 | Solid forms of an FGFR inhibitor and processes for preparing the same | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250368640-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-12-04 | — | — | US | disclosed |
| US-20250276970-A1 | DERIVATIVES OF AN FGFR INHIBITOR | INCYTE CORPORATION | 2025-09-04 | — | — | US | disclosed |
| EP-4598918-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-08-13 | — | — | EP | disclosed |
| EP-4540246-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-04-23 | — | — | EP | disclosed |
| US-11407750-B2 | Derivatives of an FGFR inhibitor | INCYTE CORPORATION (US) | 2022-08-09 | — | — | US | disclosed |
| US-20210171522-A1 | DERIVATIVES OF AN FGFR INHIBITOR | INCYTE CORPORATION | 2021-06-10 | — | — | US | disclosed |
| WO-2021113462-A1 | DERIVATIVES OF AN FGFR INHIBITOR | INCYTE CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113462-A1 | DERIVATIVES OF AN FGFR INHIBITOR | INCYTE CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| CN-112867716-A | Solid forms of FGFR inhibitors and methods for their preparation | 因赛特公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3788047-A2 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | Incyte Corporation (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20190337948-A1 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | WILMINGTON PHARMATECH | 2019-11-07 | — | — | US | disclosed |
| WO-2018191587-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | PIK3CA, MAP3K1, MAP3K5 | HTT 4191/4885KMT2A 680/4885TP53 176/4885 |
| US-20210171522-A1 | DERIVATIVES OF AN FGFR INHIBITOR | FGFR1, FGFR2, FGFR4 | HTT 2639/4885KMT2A 892/4885TP53 1099/4885 |
| US-20190337948-A1 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | FGFR1, FGFR2, FGFR3 | HTT 2314/4885KMT2A 745/4885TP53 85/4885 |
| US-20250276970-A1 | DERIVATIVES OF AN FGFR INHIBITOR | FGFR1, FGFR2, FGFR4 | HTT 2639/4885KMT2A 892/4885TP53 1099/4885 |
| US-20260108521-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | GHSR, GSPT1, GLRA1 | HTT 337/4885KMT2A 4189/4885TP53 2882/4885 |
| US-11407750-B2 | Derivatives of an FGFR inhibitor | FGFR1, FGFR2, FGFR4 | HTT 2639/4885KMT2A 892/4885TP53 1099/4885 |
| US-20250368640-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | MAP4K1, MAP4K4, MAP4K5 | HTT 504/4885KMT2A 929/4885TP53 546/4885 |
| US-12552792-B2 | Solid forms of an FGFR inhibitor and processes for preparing the same | FGFR2, FGFR1, FGF2 | HTT 4762/4885KMT2A 2450/4885TP53 445/4885 |
| US-20260103465-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | GSK3A, GSK3B, GYS2 | HTT 2531/4885KMT2A 3195/4885TP53 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.